PRO-LAD

PRO-LAD
Chemical Nomenclature
Common names	PRO-LAD
Substitutive name	6-Propyl-6-nor-lysergic acid diethylamide
Systematic name	(8β)-N,N-Diethyl-6-propyl-9,10-didehydroergoline-8-carboxamide
Class Membership
Psychoactive class	Psychedelic
Chemical class	Lysergamide
Routes of Administration
WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section. ⇣ Oral Dosage Threshold 20 µg Light 50 - 100 µg Common 100 - 200 µg Strong 200 - 350 µg Heavy 350 µg + Duration Total 6 - 8 hours Onset 30 - 45 minutes DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.
Interactions

Summary sheet: PRO-LAD

PRO-LAD (or 6-propyl-6-nor-lysergic acid diethylamide) is a psychedelic hallucinogenic drug of the lysergamide family.

This substance has little to no history of human usage. It was first investigated by Andrew J. Hoffman and David E. Nichols in 1984 as part of a series of LSD analogues, also including AL-LAD and ETH-LAD. . It was later described as an analog of LSD by Alexander Shulgin in the book TiHKAL. It is around as potent as LSD itself with an active dose reported at between 100 and 200 micrograms.

Chemistry

PRO-LAD, or 6-propyl-6-nor-lysergic acid diethylamide, is a semi-synthethic alkaloid of the lysergamide famiy. PRO-LAD is a structural analogue of lysergic acid with an N,N-diethylamide functional group bound to R_N of the chemical structure. This core polycyclic structure is an ergoline derivative and has tryptamine and phenethylamine groups embedded within it. The structure of PRO-LAD contains a bicyclic hexahydroindole fused to a bicyclic quinoline group (nor-lysergic acid).

PRO-LAD does not contain a methyl group substituted at R₆ of its nor-lysgeric acid skeleton; this is represented by the nor- prefix. Instead, PRO-LAD is substituted at R₆ with a propyl group. At R₈ of the structure, a N,N-diethyl carboxamide is bound. PRO-LAD is a chiral compound with two stereocenters at R₅ and R₈. PRO-LAD, also called (+)-D-PRO-LAD, has an absolute configuration of (5R, 8R). PRO-LAD is a derivative of LSD, differing by the addition of two carbons to the methyl group at R₆ of the structure to form a propyl chain. PRO-LAD is also homologous to ETH-LAD, which contains an ethyl substitution at R₆ instead of a propyl chain.

Pharmacology

Further information: Serotonergic psychedelic

PRO-LAD likely acts as a 5-HT_2A partial agonist. The psychedelic effects are believed to come from PRO-LAD's efficacy at the 5-HT_2A receptors. However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive.

Subjective effects

This subjective effects section is a stub. As such, it is still in progress and may contain incomplete or wrong information. You can help by expanding or correcting it.

Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.

It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.

Physical effects

• Spontaneous tactile sensations
• Increased heart rate
• Nausea
• Pupil dilation

Cognitive effects

• Conceptual thinking
• Cognitive euphoria
• Delusions
• Emotion enhancement
• Immersion enhancement
• Increased music appreciation
• Memory suppression
  • Ego death
• Novelty enhancement
• Personal bias suppression
• Thought loops
• Time distortion
• Unity and interconnectedness

Visual effects

Enhancements

• Colour enhancement
• Pattern recognition enhancement
• Visual acuity enhancement

Distortions

• Drifting (melting, breathing, morphing and flowing)
• Colour shifting
• Depth perception distortions
• Perspective distortions
• Symmetrical texture repetition
• Tracers
• After images
• Brightness alteration
• Diffraction

Geometry

Hallucinatory states

• Transformations
• Internal hallucinations (autonomous entities; settings, sceneries, and landscapes; alterations in perspective and scenarios and plots)

Auditory effects

• Enhancements
• Distortions
• Hallucinations

Toxicity and harm potential

Further information: Research chemicals § Toxicity and harm potential, and Responsible use § Hallucinogens

The toxicity and long-term health effects of recreational PRO-LAD do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because PRO-LAD is a research chemical with very little history of human usage. Anecdotal evidence from people within the psychonaut community who have tried PRO-LAD suggests that there are no negative health effects attributed to simply trying the drug by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

It is strongly recommended that one use harm reduction practices when using this drug.

Tolerance and addiction potential

PRO-LAD is not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating.

Tolerance to the effects of PRO-LAD are built almost immediately after ingestion. After that, it takes about 3 days for the tolerance to be reduced to half and 7 days to be back at baseline (in the absence of further consumption). PRO-LAD presents cross-tolerance with [[Cross-tolerance::all psychedelics]], meaning that after the consumption of PRO-LAD all psychedelics will have a reduced effect.

Legal issues

This legality section is a stub. As such, it may contain incomplete or wrong information. You can help by expanding it.

• United Kingdom: As of January 7th, 2015, PRO-LAD is specifically named in the U.K. Misuse of Drugs Act as a Class A drug.
• Switzerland: On December 1, 2015, Switzerland added PRO-LAD to the list of controlled substances.
• Latvia - PRO-LAD is illegal in Latvia. Although it isn't officially scheduled, it is controlled as an LSD structural analog due to an amendment made on June 1th, 2015.

See also

• Responsible use
• Lysergamide
• Psychedelic
• LSD
• AL-LAD
• ETH-LAD
• 1P-LSD

External links

• PRO-LAD (Wikipedia)
• PRO-LAD (TiHKAL)

Literature

• Nichols, D. E. (2016). Psychedelics, (April), 264–355.https://doi.org/10.1124/pr.115.011478
• Andrew J. Hoffman, David E. Nichols. 'Synthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives. In: Journal of Medicinal Chemistry. 28, 1985, p. 1252–1255, doi:10.1021/jm00147a022.
• V. J. Watts, R. B. Mailman, C. P. Lawler, K. A. Neve, D. E. Nichols: LSD and structural analogs: pharmacological evaluation at D1 dopamine receptors. In: Psychopharmacology. 118, 1995, p. 401–409, doi:10.1007/BF02245940.
• T. Niwaguchi, Y. Nakahara, H. Ishii: Studies on lysergic acid diethylamide and related compounds. IV. Syntheses of various amide derivatives of norlysergic acid and related compounds. In: Yakugaku Zasshi. Vol. 96, No. 5, May 1976, p. 673–678, PMID 987200.
• Robert C. Pfaff, Xuemei Huang, Danuta Marona-Lewicka, Robert Oberlender and David E. Nichols: Lysergamides Revisited. In: NIDA Research Monograph 146: Hallucinogens: An Update. p. 52, 1994, United States Department of Health and Human Services.
• Vollenweider, F. X., & Kometer, M. (2010). The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nature Publishing Group, 11(9), 642–651. https://doi.org/10.1038/nrn2884
• Nichols, D. E. (2004). Hallucinogens. Pharmacology and Therapeutics, 101(2), 131–181. https://doi.org/10.1016/j.pharmthera.2003.11.002
• Halberstadt, A. L. (2015). Recent advances in the neuropsychopharmacology of serotonergic hallucinogens. Behavioral Brain Research, 277, 99–120. https://doi.org/10.1016/j.bbr.2014.07.016